Drug Profile
Research programme: autologous T cell receptor cancer therapeutics - Kite Pharma/Netherlands Cancer Institute
Alternative Names: TCR cancer immunotherapy - Kite Pharma/ Netherlands Cancer Institute; TCR-based immuno-oncology therapeutics - Kite Pharma/Netherlands Cancer InstituteLatest Information Update: 07 Jan 2022
Price :
$50
*
At a glance
- Originator Netherlands Cancer Institute
- Class
- Mechanism of Action Cell replacements; T-cell receptor gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours